As of November 14, 2026, C4 Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on May 15, 2026 (Form 8-K, May 15, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like C4 Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
C4 Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-05-15. Every row below is cited to the filing it comes from, and this page adds each new change as C4 Therapeutics, Inc. files it.
Layoffs on record: about 45 jobs, latest 2024-01-09 (layoff filings and notices).
Also on the record for C4 Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by Lynx1 Capital Management LP | 9.99% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by RA Capital Management, L.P. | 9.9% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Squadron Master Fund LP | 6.9% of the class | 5%+ stakes | Source |
| August 12, 2026 | Stake report, Schedule 13G/A, by Morgan Stanley | 8% of the class | 5%+ stakes | Source |
| July 27, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 6.9% of the class | 5%+ stakes | Source |
| May 19, 2026 | Stake report, Schedule 13G, by Squadron Master Fund LP | 5% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Sirenia Capital Management LP | 9.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Point72 Asset Management, L.P. | 0.2% of the class | 5%+ stakes | Source |
| April 22, 2026 | Stake report, Schedule 13G/A, by Wasatch Advisors LP | 4.7% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Lynx1 Capital Management LP | 7.3% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by OrbiMed Capital LLC | 1% of the class | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13G/A, by Soleus Capital Master Fund, L.P. | 9.99% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs C4 Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on C4 Therapeutics, Inc. and the records around it.
C4 Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Bain Capital Life Sciences Fund II, L.P. also filed stake reports on 2 other companies: Xilio Therapeutics, Inc. (May 2026)
- Lynx1 Capital Management LP also filed stake reports on 11 other companies: GH Research PLC (Aug 2026), iBio, Inc. (Aug 2026), Stoke Therapeutics, Inc. (Aug 2026)
- Squadron Master Fund LP also filed stake reports on 14 other companies: Contineum Therapeutics, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), NextCure, Inc. (Aug 2026)
Watch C4 Therapeutics, Inc.
Get an email when C4 Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on C4 Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on C4 Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on C4 Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 20 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-15 | Reported | not named in the filing | 8-K, 2026-05-15 |
New leaders reset buying decisions — get the Full Report on C4 Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at C4 Therapeutics, Inc., with the record behind each one.
Find candidates like senior executive at C4 Therapeutics, Inc.Every change, in the filing's words
Reported
Mr. Mossler's departure from the Company is not due to any disagreement with the Company or the Company's Board of Directors on any matter relating to the Company's financial reporting, operations, policies or practices.
- Departure of Principal Accounting Officer On May 12, 2026, C4 Therapeutics, Inc. (the "Company") determined that Mark Mossler will no longer serve as the Company's Chief Accounting Officer, effective May 15, 2026.
- Appointment of Principal Accounting Officer Kendra R. Adams, the Company's Chief Financial Officer, Head of Corporate Affairs and Treasurer, has been designated as the Company's principal accounting officer, effective May 15, 2026.
- Ms. Adams will not receive any additional compensation for assuming the additional role of principal accounting officer, and no changes have been made to any plans or arrangements in which Ms. Adams participates as a result of this appointment.
Tools for this story
Each opens in a new tab, filled in for C4 Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
